Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-30T21:51:41.287Z Has data issue: false hasContentIssue false

Recovery in schizophrenia: the role of antipsychotic treatment

Published online by Cambridge University Press:  27 August 2024

I. Bitter*
Affiliation:
Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Comprehensive care programs, which include individually planned pharmacotherapy are associated with higher rates of recovery1 and better long-term prognosis2. However, there are barriers to individually optimised antipsychotic treatment both from both the patients and treatment teams perspectives.

Objectives

To summarize the potential contribution of adequate long-term antipsychotic treatment to recovery or better outcomes in schizophrenia.

Method

Review of research data.

Results A shorter duration of untreated psychosis, a lower number of relapses, and the absence of a chronic course of psychosis are associated with higher rates of recovery and a better prognosis. The OPUS early intervention program was associated with better outcomes for up to 10 years, but not for more than 20 years3. Second generation antipsychotics are associated with lower mortality rates, including suicides in young people with schizophrenia.4

Higher doses of antipsychotics are associated with poorer outcomes and with potential structural brain changes, while adequate (lower) doses of antipsychotics are associated with lower side effect burden and better overall outcomes5. A significant proportion of patient may benefit from polypharmacy (combination of 2 antipsychotics)6. Antipsychotic treatment discontinuation strategies are associated with the development of treatment resistance.7

Conclusions

Adequate (low dose) antipsychotic treatment is part of the complex early intervention programs and long term treatment of schizophrenia, which are associated with higher rates of recovery and good outcomes. The role of polypharmacy (combination of 2 antipsychotics) may need a reconsideration in the treatment guidelines of schizophrenia.

  1. 1. Kane JM et al. The Journal of clinical psychiatry. 2015 Mar 25;76(3):16590.

  2. 2. Posselt CM et al. 2021. American Journal of Psychiatry, 2021, 178(10):941-951

  3. 3. Hansen HG et al. 2023. JAMA Psychiatry, 2023, 80(4): 371-379.

  4. 4. Correll CU et al. World Psychiatry. 2022 Jun;21(2):248-71.

  5. 5. Andreasen NC et al. 2013 Jun;170(6):609-15.

  6. 6. Katona L et al. 2014 Jan 1;152(1):246-54.

  7. 7. Emsley R et al2013 Feb 1;33(1):80-3.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.